Skip to main content
Premium Trial:

Request an Annual Quote

NIMH Offering $5M for Genomic Approaches to Bipolar Disorder, Schizophrenia

NEW YORK (GenomeWeb News) —The National Institute of Mental Health will fund seven or eight grants with a total of around $5 million to use genomic approaches to study schizophrenia and bipolar disorder, the National Institutes of Health said last week.
The funding, which will go to both R01 and R01 collaborative awards, is aimed at expanding existing resources for schizophrenia and bipolar disorder research under the NIMH’s Human Genetics Initiative. Researchers will use the funds to apply genomic and related tools to advance the knowledge of the molecular origins of these diseases.
Areas of investigation under these grants may include, but are not limited to, combining data sets generated under this initiative with existing ones to replicate previous findings or detect additional genes underlying these disorders; combining samples from different studies using different methods and studying innovative and cost-sparing ways for phenotypic and genomic analyses; conducting studies that allow for rapid and cost-effective ascertainment, recruitment, and clinical assessment of study subjects for large-scale genetic studies of schizophrenia or bipolar disorder; analyzing genes known to be related to development of mental disorders; and conducting high-density, whole-genome association analyses using existing technology platforms for SNP typing.
There are no specific budget or project term limits for the research, aside from the standard five-year budget limit. Letters of intent are due April 7 and applications are due May 6.
“Applications submitted in response to this initiative should focus on the rapid collection of large cohorts of clinically well-characterized populations of schizophrenia or bipolar subjects and controls (if appropriate) on a topic related to the genomic or genetic analysis of these traits, employing innovative analytical study designs,” the NIH said in its announcement. “The ultimate goal of successful applications will be to identify specific genomic and functional variants that influence susceptibility to schizophrenia and bipolar disorder.”

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.